Cofoe Medical Technology Co., Ltd. (“Cofoe Medical”) released an updated Articles of Association effective June 2026, detailing governance, capital structure and profit-allocation rules following its recent Hong Kong listing. Key points are as follows:

• Capital & Share Structure – Registered capital is confirmed at RMB235.90 million, comprising 208.90 million A-shares on Shenzhen’s ChiNext and 27.00 million H-shares listed on HKEX on 6 May 2026.

• Listing Timeline – The company floated 40.00 million A-shares in October 2021 and completed an additional 27.00 million H-share offering in Hong Kong on 6 May 2026.

• Business Scope – The charter authorises production and sales of Class I–III medical devices, protective medical supplies, disinfectants, cosmetics and bio-based materials, alongside R&D, technical services and import–export activities.

• Governance Framework – The Board consists of seven directors, including three independent directors and one employee representative. An Audit Committee replaces a traditional supervisory board and is composed of three non-executive directors (two independents). Special committees cover strategy, nomination and remuneration.

• Dividend Policy – At least 30% of average annual distributable profit over any three-year period must be returned to shareholders in cash, with priority on annual distributions. Interim dividends are permissible subject to liquidity and investment needs; share dividends may be issued when rapid growth dilutes per-share metrics.

• Capital Management – Share buy-backs are allowed for capital reduction, employee incentives, bond conversion or value protection, but cumulative treasury shares cannot exceed 10% of total share capital and must be cancelled or transferred within statutory deadlines.

• Shareholder Protections – A single shareholder, director or senior executive who trades shares within six months of opposite transactions must forfeit gains to the company. Related-party shareholders are excluded from voting on connected transactions exceeding RMB30 million and 5% of net assets.

• Party Leadership – The document formalises a CPC committee within Cofoe Medical, integrated into corporate governance with dedicated personnel, funding and decision-making responsibilities.

The revised Articles provide a comprehensive corporate framework aligning Cofoe Medical’s mainland and Hong Kong regulatory obligations after completing its dual-listing strategy.